Compare FPH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | ABEO |
|---|---|---|
| Founded | 2009 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.9M | 399.5M |
| IPO Year | 2013 | 2005 |
| Metric | FPH | ABEO |
|---|---|---|
| Price | $4.58 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 143.8K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,020,000.00 | $2,998,000.00 |
| Revenue This Year | $1,459.63 | $804.33 |
| Revenue Next Year | $5.38 | $119.68 |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $4.55 | $4.00 |
| 52 Week High | $6.47 | $7.65 |
| Indicator | FPH | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 35.55 |
| Support Level | $4.57 | $4.94 |
| Resistance Level | $5.18 | $5.46 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 15.40 | 11.39 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.